AbbVie wins second AndroGel liability reversal

Jul 09, 2018

 A U.S. judge overturned a $140.1 million verdict against AbbVie in a lawsuit by a man who claimed the drugmaker misrepresented the risks of its testosterone replacement drug AndroGel, which caused him to suffer a heart attack.

U.S. District Judge Matthew Kennelly in Chicago ordered a retrial in the lawsuit brought by Tennessee resident Jeffrey Konrad, ruling that the jury's finding on the negligence claim was inconsistent with its decision to find AbbVie not liable on another claim.

The case marks the second major reversal, as AbbVie faces 4,500 cases nationally over injuries blamed on AndroGel. Plaintiffs claim the company did not adequately warn about risks of heart attacks, strokes and blood clots that could result from using AndroGel.

Read the Reuters coverage